dea
-
How 4 Mental Health Firms Want the DEA to Handle Virtual Prescribing of Controlled Substances
Talkiatry, Array Behavioral Care, Iris Telehealth and Quartet Health sent a letter to the DEA asking for a special registration process that would allow for the prescribing of certain controlled medications via telemedicine.
-
Providers Mostly Agree with the AMA’s Views on Controlled Substance Prescribing Via Telemedicine
The American Medical Association recently released its comments on the DEA’s proposed rules for controlled substance prescribing via telemedicine. Many telehealth providers are supportive of the organization’s recommendations, such as its suggestion to extend the timeframe patients have to refill their buprenorphine prescription after their initial supply is prescribed via telemedicine.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
‘The Stakes Couldn’t Be Higher’: How DEA’s Proposal Will Affect Telehealth Controlled Substance Prescribing
The DEA recently released proposed rules that would require an in-person visit before a patient can receive a telehealth prescription for a controlled substance. The DEA touts the change as a way to ensure patient safety, but several telehealth advocates argue it will greatly disrupt access for those who need the drugs — especially at a time when the mental health and substance use crisis is growing.
-
Ohio’s $650 million opioid ruling against major pharmacies may spook pharmacists
“This decision sends pharmacists a dangerous message: you’re expected to overrule doctors – and not doing so can be costly.”
-
DEA to reschedule hydrocodone combination products
By Delia A. Deschaine & Larry K. Houck – In just shy of three months […]
-
DEA moves swiftly in issuing final rule placing FYCOMPA in Schedule III drugs
By Delia A. Stubbs & John A. Gilbert – DEA didn’t waste time during its […]
-
FDA petitioned twice more to delay start of Hatch-Waxman exclusivity
By Kurt R. Karst – The number of citizen petitions pending at FDA concerning Hatch-Waxman exclusivity continues to pile up. As we previously reported (here and here), FDA has already been asked on three separate occasions in 2013 to recognize…
-
DEA releases 2013 Drug Threat Assessment Summary
By Karla L. Palmer – On Monday, November 18, 2013, DEA released the 2013 National Drug Threat Assessment Summary, which provides an assessment of the threat posed to the United States by trafficking and abuse of illicit substances and non-medical…
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
